CD8+ T cells are critical players in anti-tumor immunity against solid tumors, targeted by immunotherapies. Emerging evidence suggests that CD8+ T cells also play a crucial role in anti-tumor responses and determining treatment outcomes in hematologic malignancies like myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). In this review, we focus on the implication of CD8+ T cells in the treatment response of patients with MDS and AML. First, we review reported studies of aberrant functionality and clonality of CD8+ T cells in MDS and AML, often driven by the immunosuppressive bone marrow microenvironment, which can hinder effective antitumor immunity. Additionally, we discuss the potential use of CD8+ T cell subpopulations, including memory and senescent-like subsets, as predictive biomarkers for treatment response to a variety of treatment regimens, such as hypomethylating agents, which is the standard of care for patients with higher-risk MDS, and chemotherapy which is the main treatment of patients with AML. Understanding the multifaceted role of CD8+ T cells and their interaction with malignant cells in MDS and AML will provide useful insights into their potential as prognostic/predictive biomarkers, but also uncover alternative approaches to novel treatment strategies that could reshape the therapeutic landscape, thus improving treatment efficacy, aiding in overcoming treatment resistance and improving patient survival in these challenging myeloid neoplasms.
CD8+ T cells are critical players in anti-tumor immunity against solid tumors, targeted by immunotherapies. Emerging evidence suggests that CD8+ T cells also play a crucial role in anti-tumor responses and determining treatment outcomes in hematologic malignancies like myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). In this review, we focus on the implication of CD8+ T cells in treatment response of patients with MDS and AML. First, we review reported studies of aberrant functionality and clonality of CD8+ T cells in MDS and AML, often driven by the immunosuppressive bone marrow microenvironment, which can hinder effective antitumor immunity. Additionally, we discuss the potential use of CD8+ T cell subpopulations, including memory and senescent-like subsets, as predictive biomarkers for treatment response to a variety of treatment regimens, such as hypomethylating agents which is the standard of care for patients with higher-risk MDS, and chemotherapy which is the main treatment of patients with AML. Understanding the multifaceted role of CD8+ T cells and their interaction with malignant cells in MDS and AML, will provide useful insights into their potential as prognostic/predictive biomarkers, but also uncover alternative approaches to novel treatment strategies that could reshape the therapeutic landscape, thus improving treatment efficacy, aiding in overcoming treatment resistance and improving patient survival in these challenging myeloid neoplasms.
Azacytidine is the only approved treatment for patients with higher-risk myelodysplastic syndromes (MDS); yet less than half of the patients will achieve a response, whereas the duration of response is highly heterogeneous and there are no predictors for response duration. The aim of this study is to estimate the patient’s time to loss of response (LoR) to azacytidine based on clinical measurements during treatment. To this end, a personalized prediction framework is proposed that estimates the LoR of a new patient using a patient similarity-based approach. Namely, the new patient’s clinical data—represented as a multivariate time series—are compared to a reference set of patients. The comparison uses distance metrics that quantify how similar two patients’ time series are, assuming patients with similar trajectories tend to have similar LoR. Then, the LoR of the new patient is predicted by averaging the outcomes of the most similar reference patients. The pipeline includes a data normalization strategy that centers each feature on its baseline value and scales it to highlight relative changes and distance metrics to quantify similarity. Both real-world and simulated data were utilized to evaluate the proposed methodology, employing the leave-one-out validation and the Mean Absolute Percentage Error (MAPE) to assess accuracy. The estimated MAPE was found to be 30.52% and 11.82% in the real-world and simulated dataset, respectively. The best and most robust predictions were achieved using the Euclidean distance metric and setting the number of most similar patients around three to five. This study proposes a personalized predictive approach for the LoR to azacitidine in the MDS clinical setting, demonstrating potential for a serviceable prediction of LoR and forming the foundation for further research.